Kuros Biosciences AG (LON:0RHR)
London · Delayed Price · Currency is GBP · Price in CHF | Market Cap | 748.55M -12.5% |
| Revenue (ttm) | 108.52M +71.5% |
| Net Income | 1.90M |
| EPS | 0.05 |
| Shares Out | n/a |
| PE Ratio | 394.93 |
| Forward PE | 80.28 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 914 |
| Average Volume | 24,296 |
| Open | 20.20 |
| Previous Close | 20.15 |
| Day's Range | 20.16 - 20.34 |
| 52-Week Range | 18.82 - 34.08 |
| Beta | 0.70 |
| RSI | 41.00 |
| Earnings Date | Aug 13, 2026 |
About Kuros Biosciences AG
Kuros Biosciences AG engages in the commercialization and development of biologic technologies for musculoskeletal care in the United States of America, the European Union, and internationally. It operates through two segments, Medical Devices and Legacy Portfolio. The company provides MagnetOs Granules, an advanced bone graft based on the submicron needle-shaped NeedleGrip surface technology; MagnetOs Putty, a mold uses to fill bony voids for intervertebral disc space or posterolateral spine; and Attrax, a biphasic calcium phosphate bone graft... [Read more]
News
Kuros Biosciences appoints I.V. Hall as Chief Operating Officer, deepening operational, R&D and extremities leadership for next phase of growth
Kuros Biosciences appoints I.V. Hall as Chief Operating Officer, deepening operational, R&D and extremities leadership for next phase of growth
Kuros Biosciences reports 51% year-over-year increase in sales in the first three months of 2026
Ad hoc announcement pursuant to Article 53 of the SIX listing rules Kuros Biosciences reports 51% year-over-year increase in sales in the first three months of 2026 Financial Highlights Total product ...